Full Text
REGD. No. D. L.-33004/99
The Gazette of India
CG-DL-E-15052024-254199
EXTRAORDINARY
PART II-Section 3-Sub-section (ii)
PUBLISHED BY AUTHORITY
No. 1896]
NEW DELHI, WEDNESDAY, MAY 15, 2024/VAISAKHA 25, 1946
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 15th May, 2024
S.O. 1990(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022 issued by
the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority
(hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail
price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry
in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified
in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| SI. | Medicines | Strength | Unit | Manufacturer & | Retail |
| No. | | | | Marketing Company | Price |
| | | | | | (Rs.) |
+=====+===================================+================================================================================================================================================================================================+================+=============================================================+================+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 1 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 14.75 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 2 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 14.53 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 3 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Akums Drugs & | 14.75 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 4 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 16.00 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s La Renon Healthcare Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 5 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 16.24 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 6 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Akums Drugs & | 16.43 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Pharmaceuticals Ltd. / M/s Abbott Healthcare Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg (As Extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 7 | Sitagliptin Phosphate, Metformin | Each film coated Tablet contains: | 1 Tablet | M/s Mascot Health | 13.35 |
| | Hydrochloride and Glimepiride | Sitagliptin Phosphate Monohydrate | | Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | |
| | Tablets | IP eq. to Sitagliptin 50mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 8 | Sitagliptin Phosphate, Metformin | Each film coated Tablet contains: | 1 Tablet | M/s Mascot Health | 15.03 |
| | Hydrochloride and Glimepiride | Sitagliptin Phosphate Monohydrate | | Series Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | |
| | Tablets | IP eq. to Sitagliptin 50mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 1000mg | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 9 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 13.24 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 500mg (As Extended release) | | | |
| | | Glimepiride IP 1 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 10 | Dapagliflozin, Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health | 14.83 |
| | Hydrochloride (Extended Release) | Dapagliflozin Propanediol USP eq. | | Series Pvt. Ltd. / M/s Primus Remedies Pvt. Ltd. | |
| | and Glimepiride Tablets | to Dapagliflozin 10mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 500mg (As Extended release) | | | |
| | | Glimepiride IP 2 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 11 | Diclofenac Diethylamine, Methyl | Composition: | 1 gm | M/s Pontika Aerotech Limited/M/s Unison Pharmaceuticals | 2.73 |
| | Salicylate, Virgin Linseed Oil & | Diclofenac Diethylamine IP 1.16% w/w eq. to Diclofenac Sodium 1.00% w/w, | | Pvt. Ltd. | |
| | Menthol Topical spray | Methyl Salicylate IP 10.00% w/w, | | | |
| | | Virgin Linseed Oil BP 3.0% w/w, | | | |
| | | Menthol IP 5.00% w/w | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 12 | Povidone-Iodine & Ornidazole | Composition: | 1 gm | M/s Curetech Skincare / M/s J.B. Chemicals & | 4.11 |
| | Ointment | Povidone-Iodine IP 5%w/w | | Pharmaceuticals Ltd. | |
| | | (Available Iodine 0.5%w/w) | | | |
| | | Ornidazole IP 1% w/w in an | | | |
| | | Ointment base | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 13 | Bisoprolol Fumarate and | Each film coated Tablet contains: | 1 Tablet | M/s Ravenbhel Healthcare Pvt Ltd / M/s J.B. Chemicals & | 11.21 |
| | Telmisartan Tablets | Bisoprolol Fumarate IP 5 mg | | Pharmaceuticals Ltd. | |
| | | Telmisartan IP 40 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 14 | Bisoprolol Fumarate and | Each film coated Tablet contains: | 1 Tablet | M/s Ravenbhel Healthcare Pvt Ltd / M/s J.B. Chemicals & | 9.65 |
| | Telmisartan Tablets | Bisoprolol Fumarate IP 2.5 mg | | Pharmaceuticals Ltd. | |
| | | Telmisartan IP 40 mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 15 | Cefixime and Ofloxacin Oral | Each 5ml reconstituted suspension contains: | 1 ml | M/s Innova Captab Ltd. / M/s Emcure Pharmaceuticals Ltd. | 1.90 |
| | suspension | Cefixime IP as trihydrate eq. to | | | |
| | | Cefixime Anhydrous 50mg | | | |
| | | Ofloxacin IP 50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 16 | Ibuprofen & Paracetamol Tablets | Each uncoated Tablet contains: | 1 Tablet | M/s Prochem Pharmaceuticals Pvt. Ltd. / M/s Softdeal | 1.59 |
| | | Ibuprofen IP 400mg | | Pharmaceuticals Private Limited | |
| | | Paracetamol IP 325mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 17 | Ranitidine Hydrochloride, | Each film coated Tablet contains: | 1 Tablet | M/s IndocoRemedies Limited | 2.09 |
| | Dicyclomine Hydrochloride & | Ranitidine Hydrochloride IP eq. to | | | |
| | Activated Simethicone Tablet | Ranitidine 150mg | | | |
| | | Dicyclomine Hydrochloride IP | | | |
| | | 10mg | | | |
| | | Activated Dimethicone IP | | | |
| | | (Simethicone) 20mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 18 | Telmisartan, Amlodipine & | Each film coated Tablet contains: | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Torrent | 15.96 |
| | Hydrochlorothiazide Tablets | Telmisartan IP 80mg, | | Pharmaceuticals Ltd. | |
| | | Amlodipine Besilate IP eq. to | | | |
| | | Amlodipine 5mg | | | |
| | | Hydrochlorothiazide IP 12.50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 19 | Telmisartan, Amlodipine & | Each film coated Tablet contains: | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Torrent | 10.45 |
| | Hydrochlorothiazide Tablets | Telmisartan IP 40mg, | | Pharmaceuticals Ltd. | |
| | | Amlodipine Besilate IP eq. to | | | |
| | | Amlodipine 5mg | | | |
| | | Hydrochlorothiazide IP 12.50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 20 | Ceftazidime and Avibactam (As | Each vial contains: | 1 Vial | M/s Aqua Vitoe Laboratories / M/s Emcure | 1569.94 |
| | Sodium Salt) powder for | Ceftazidime Pentahydrate (Sterile) | | Pharmaceuticals Limited | |
| | concentrate for solution for | eq. to Ceftazidime IP 2.0gm | | | |
| | infusion | Avibactam Sodium (Sterile) eq. to | | | |
| | | Avibactam 0.5gm | | | |
| | | Sterile Sodium Carbonate IP | | | |
| | | (anhydrous) 232.9mg | | | |
| | | Sodium per vial content 6.44 mmol | | | |
| | | eq. to 148mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 21 | Glimepiride & Metformin | Each uncoated bilayered Tablet contains: | 1 Tablet | M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd. | 11.28 |
| | Hydrochloride (ER) Tablets | Glimepiride IP 4mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 500mg (In extended-release form) | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 22 | Glimepiride & Metformin | Each uncoated bilayered Tablet contains: | 1 Tablet | M/s Innova Captab Ltd. / M/s Cadila Pharmaceuticals Ltd. | 9.84 |
| | Hydrochloride (ER) Tablets | Glimepiride IP 3mg | | | |
| | | Metformin Hydrochloride IP | | | |
| | | 500mg (In extended release form) | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 23 | Bilastine and Montelukast oral | Each 5ml suspension contains: | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Sun | 1.72 |
| | suspension | Bilastine 10mg | | Pharmaceuticals Industries Limited | |
| | | Montelukast Sodium IP eq. to | | | |
| | | Monelukast 4mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 24 | Aceclofenac, Paracetamol & | Each film coated Tablet contains: | 1 Tablet | M/s Innova Captab Ltd./M/s Mankind Pharma Ltd. | 25.98 |
| | Thiocolchicoside Tablets | Aceclofenac IP 100mg | | | |
| | | Paracetamol IP 325mg | | | |
| | | Thiocolchicoside IP 8mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 25 | Aceclofenac, Paracetamol & | Each film coated Tablet contains: | 1 Tablet | M/s Innova Captab Ltd. / M/s Mankind Pharma Ltd. | 18.05 |
| | Thiocolchicoside Tablets | Aceclofenac IP 100mg | | | |
| | | Paracetamol IP 325mg | | | |
| | | Thiocolchicoside IP 4mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 26 | Hydrocortisone Acetate, | Each suppository contains: | 1 Suppository | M/s Bliss GVS Pharma Ltd. / M/s Zydus Healthcare Limited | 14.30 |
| | Lidocaine, Zinc Oxide & Allantoin | Hydrocortisone Acetate IP 0.25% | | | |
| | Suppositories | w/w | | | |
| | | Lidocaine USP 3.0% w/w | | | |
| | | Zinc Oxide IP 5.0% w/w | | | |
| | | Allantoin IP 0.5% w/w | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 27 | Ciprofloxacin & Tinidazole Tablet | Each film coated Tablet contains: | 1 Tablet | M/s Aagya Biotech Pvt. Ltd./M/s J. B. Chemicals & | 10.64 |
| | | Ciprofloxacin Hydrochloride IP eq. | | Pharmaceuticals Ltd. | |
| | | to Ciprofloxacin 500mg | | | |
| | | Tinidazole IP 600mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 28 | Fexofenadine Hydrochloride & | Each film coated Tablet contains: | 1 Tablet | M/s Aagya Biotech Pvt. Ltd./M/s J. B. Chemicals & | 15.10 |
| | Montelukast Tablet | Fexofenadine Hydrochloride IP | | Pharmaceuticals Ltd. | |
| | | 120mg | | | |
| | | Montelukast Sodium IP eq. to | | | |
| | | Montelukast 10mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 29 | Antacid Antigas gel | Each 10ml (two teaspoonful) | 1 ml | M/s Intas Pharmaceuticals Pvt. Ltd. | 0.56 |
| | | contains: | | | |
| | | Dried Aluminium Hydroxide Gel | | | |
| | | IP (added as paste) 830mg | | | |
| | | Magnesium Hydroxide IP (added | | | |
| | | as paste) 185mg | | | |
| | | Sodium Carboxymethylcellulose IP | | | |
| | | 100mg | | | |
| | | Simethicone IP 50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 30 | Bisoprolol Fumarate and | Each film coated Tablet contains: | 1 Tablet | M/s Savi Health Science / M/s Alkem Laboratories Ltd. | 6.40 |
| | Amlodipine Tablets | Bisoprolol Fumarate IP 2.5mg | | | |
| | | Amlodipine Besylate IP Eq. to | | | |
| | | Amlodipine 5mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 31 | Bisoprolol Fumarate and | Each film coated Tablet contains: | 1 Tablet | M/s Savi Health Science / M/s Alkem Laboratories Ltd. | 8.98 |
| | Amlodipine Tablets | Bisoprolol Fumarate IP 5mg | | | |
| | | Amlodipine Besylate IP Eq. to | | | |
| | | Amlodipine 5mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 32 | Atorvastatin, Clopidogrel & | Each hard gelatine capsule | 1 Capsule | M/s Windlas Biotech Limited/M/s Aristo Pharmaceuticals | 13.84 |
| | Aspirin Capsule | contains: | | Pvt. Ltd. | |
| | | Atorvastatin Calcium IP eq. to | | | |
| | | Atorvastatin 40mg (As green | | | |
| | | coloured pellets), | | | |
| | | Clopidogrel Bisulphate IP eq. to | | | |
| | | Clopidogrel 75mg (As two reddish | | | |
| | | brown coloured film coated Tablet, | | | |
| | | each containg 37.5mg Clopidogrel | | | |
| | | Tablets IP), | | | |
| | | Aspirin IP 75mg (As enteric coated | | | |
| | | white-coloured pellets) | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 33 | Levocetirizine Dihydrochloride & | Each 5ml contains: | 1 ml | M/s Aagya Biotech / M/s J. B. Chemicals & | 1.47 |
| | Montelukast Sodium suspension | Levocetirizine Dihydrochloride IP | | Pharmaceuticals Ltd. | |
| | | 2.5mg | | | |
| | | Montelukast Sodium IP eq. to | | | |
| | | Montelukast 4mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 34 | Linagliptin & Metformin | Each film coated bilayered Tablet contains: | 1 Tablet | M/s Mascot Health Series Pvt. Ltd. / M/s Mankind Pharma | 12.86 |
| | Hydrochloride (ER) Tablets | Linagliptin 5mg | | Limited | |
| | | Metformin Hydrochloride IP | | | |
| | | 500mg (as extended-release form) | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 35 | Pantoprazole & Domperidone | Each gastro-resistant Tablet | 1 Tablet | M/s Innova Captab Ltd. / Dr. Reddy's Laboratories Limited | 7.24 |
| | Tablet | contains: | | | |
| | | Pantoprazole Sodium IP (as | | | |
| | | sesquihydrate) eq. to Pantoprazole | | | |
| | | 40mg | | | |
| | | Domperidone IP 10mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 36 | Chlorpheniramine Maleate, | Each 5ml contains: | 1 ml | M/s Stedman Pharmaceuticals Pvt. Ltd. | 1.02 |
| | Dextromethorphan & Phenylephrine | Chlorpheniramine Maleate IP 2mg | | | |
| | Syrup | Phenylephrine Hydrochloride IP | | | |
| | | 5mg | | | |
| | | Dextromethorphan Hydrobromide | | | |
| | | IP 10mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 37 | Cefixime and Ofloxacin Oral | Each 5ml reconstituted suspension contains: | 1 ml | M/s Innova Captab Ltd. / Dr. Reddy's Laboratories Limited | 1.90 |
| | suspension | Cefixime IP as trihydrate eq. to | | | |
| | | Cefixime Anhydrous 50mg | | | |
| | | Ofloxacin IP 50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
Note:
(a) The manufacturer of above-mentioned formulations i.e., "new drug" under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/255/123/2024/F F. No. 8(123)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
ORDER
New Delhi, the 15th May, 2024
S.O. 1991(E).— In implementation of directions of review order issued by the Department of
Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the
table below and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices
Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 5249(E) dated 11th November, 2022
issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of
the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority)
S.O. No. and date specified in the Column (8) of the table, the National Pharmaceutical Pricing Authority, hereby
fixes/revises the price including WPI impact @0.00551% for the year 2024 as specified in column (6) of the table
herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled
formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and
unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| SI. | Medicines | Strength | Unit | Manufacturer & | Retail Price |
| No. | | | | Marketing Company | (Rs.) |
+=====+===================================+==================================================================================================================+================+=============================================================+================+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 1. | Ceftazidime and Avibactam powder | Each vial contains: | 1 Vial | M/s Protech Telelinks / M/s Samarth Life Sciences Pvt. Ltd. | 2074.74 |
| | for concentrate for solution for | Ceftazidime Pentahydrate IP | | | |
| | infusion | eq. to Ceftazidime 2.0gm | | | |
| | | Avibactam Sodium eq. to Avibactam 0.5gm | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 2. | Vitamin D3 Oral Solution | Each 5ml contains: | 1ml | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s La Renon | 11.63 |
| | | Cholecalciferol IP 600000 IU | | Healthcare Pvt. Ltd. | |
| | | (In Nano Droplet form) | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 3. | Telmisartan and Chlorthalidone | Each film coated tablet | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon | 7.39 |
| | Tablet | contains: | | Healthcare Pvt. Ltd. | |
| | | Telmisartan IP 40mg | | | |
| | | Chlorthalidone IP 12.50mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
| 4. | Telmisartan and Amlodipine Tablet | Each uncoated bilayered | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s La Renon | 13.21 |
| | | tablet contains: | | Healthcare Pvt. Ltd. | |
| | | Telmisartan IP 80mg | | | |
| | | Amlodipine Besilate IP eq. | | | |
| | | Amlodipine 5mg | | | |
+-----+-----------------------------------+------------------------------------------------------------------------------------------------------------------+----------------+-------------------------------------------------------------+----------------+
Note:
(a) The manufacturer of above-mentioned formulations i.e. "new drug" under paragraph 2(1)(u) of the DPCO,
2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form-V from date of
Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State
Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated
under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the
Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent
Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned
manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table
with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries
in Column (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified
strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2),
(3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
[PN/255/123/2024/F F. No. 8(123)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
ORDER
New Delhi, the 15th May, 2024
S.O. 1992(E).— In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the
Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated 30th May, 2013 and S.O. 5249(E) dated 11th
November, 2022 issued by the Government of India the Ministry of Chemicals and Fertilizers and in supersession of
the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing
Authority) No SO 1548(E) dated 26th March, 2024 in so far as it relates to formulation packs mentioned in the table
below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical
Pricing Authority (hereinafter referred as NPPA) hereby fixes the price as specified in column (5) of the table herein
below as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| Sl. | Medicines | Dosage form and | Unit | Manufacturer & | Ceiling Price |
| No. | | strength | | Marketing Company | (Rs.) |
+=====+==================================+==================================+================+=================================================+================+
| (1) | (2) | (3) | (4) | (5) | (6) |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 1 | Ampicillin | Powder for injection 1000 mg | 1 Vial | | 24.92 |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 2 | Cloxacillin | Capsule 500mg | 1 Capsule | | 2.38 |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 3 | Cloxacillin | Capsule 250mg | 1 Capsule | | 1.41 |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 4 | Oxaliplatin | Injection 5 mg/mL in 20ml vial | 1 Vial | | 4979.68 |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 5 | Oral Rehydration Salts | As licensed | 1 GM | | 0.99 |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
| 6 | 5-Amino Salicylic acid | Tablet 400mg | 1 Tablet | | 7.92 |
| | (Mesalazine / Mesalamine) | | | | |
+-----+----------------------------------+----------------------------------+----------------+-------------------------------------------------+----------------+
Note:
(a) All manufacturers of scheduled formulation, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling
price specified in column (5) in the above table plus goods and services tax as applicable, if any.
(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling
price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall continue
to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy
to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect
of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control)
Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this
notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/255/123/2024/F F. No. 8(123)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
ORDER
New Delhi, the 15th May, 2024
S.O. 1993(E). In implementation of directions of review order issued by the Department of
Pharmaceuticals (DOP) under para 31 of Drugs (Prices Control) Order, 2013 vide order specified in column (7) of the
table below and in exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices
Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 5249(E) dated 11th November, 2022
issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of
the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority)
S.O. No. and date specified in the Column (8) of the table, the National Pharmaceutical Pricing Authority, hereby
fixes/revises the price including WPI impact @0.00551% for the year 2024 as specified in column (6) of the table
herein below as ceiling price exclusive of Goods and Services Tax applicable, if any, in respect of the Scheduled
formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and
unit specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
+-----+-----------+------------------+----------------+-------------------------------------------------------------+-------------------------------------------------+-----------------------------------+-----------------------------------+
| Sl. | Medicines | Dosage form | Unit | Ceiling | Revised | Review Order | Existing SO |
| No. | | & Strength | | Price | Ceiling price | number and date | number and |
| | | | | under | based on | | date |
| | | | | NLEM, | Review Order | | |
| | | | | 2022 | & considering | | |
| | | | | (Rs.) | WPI | | |
| | | | | | @0.00551% | | |
| | | | | | (Rs.) | | |
+=====+===========+==================+================+=============================================================+=================================================+===================================+===================================+
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
+-----+-----------+------------------+----------------+-------------------------------------------------------------+-------------------------------------------------+-----------------------------------+-----------------------------------+
| 1. | Isoniazid | Tablet 100 mg | 1 | 0.65 | 0.73 | 31015/75/2023- | 1547(E) |
| | | | Tablet | | | Pricing dated | dated |
| | | | | | | 05.03.2024 | 26.03.2024 |
| | | | | | | | (Sl. No. 353) |
+-----+-----------+------------------+----------------+-------------------------------------------------------------+-------------------------------------------------+-----------------------------------+-----------------------------------+
Note:
(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus Goods and Services Tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling
price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any.
(b) All the existing manufacturers of above-mentioned scheduled formulations having MRP lower than the ceiling
price specified in column (6) in the above table plus Goods and Services Tax as applicable, if any, shall continue
to maintain the existing MRP in accordance with paragraph 13 (2) of the DPСО, 2013.
(c) The manufacturers may add Goods and Services Tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (6) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy
to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2(1)(u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect
of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013
through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation
shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled
formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of
discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control)
Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/255/123/2024/F F. No. 8(123)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
CORRIGENDUM
New Delhi, the 15th May, 2024
S.O. 1994(E). In the National Pharmaceutical Pricing Authority's notification S.O. 938(E)
dated 28.02.2024, further revised vide S.O. 1547(E), dated 26.03.2024 relating to fixation of ceiling price, published
in the Gazette of India, Extraordinary, the Entry at Sl. No. 25 and 722 respectively of the Table, both in Hindi &
English version, be read as follows:
Instead of
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
| Sl. No. | Medicines | Dosage form & | Unit | Ceiling Price |
+===================================+===================================+===================================+================+================+
| (1) | (2) | (3) | (4) | (5) |
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
| 25 of S.O. 938(E) dt | Budesonide (A) | Inhalation (DPI) | 1 Dose | 6.62 |
| 28.02.2024 and 722 | +Formoterol (B) | 400mcg(A) +6 mcg (B) | | |
| of S.O. 1547(E) dt | | | | |
| 26.03.2024 | | | | |
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
Read as
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
| Sl. No. | Medicines | Dosage form & Strength | Unit | Ceiling Price |
+===================================+===================================+===================================+================+================+
| (1) | (2) | (3) | (4) | (5) |
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
| 25 of S.O. 938(E) dt | Budesonide (A) | Inhalation (DPI) 400mcg (A) + | 1 Dose | 6.95 |
| 28.02.2024 and 722 | +Formoterol (B) | 6 mcg (B) | | |
| of S.O. 1547(E) dt | | | | |
| 26.03.2024 | | | | |
+-----------------------------------+-----------------------------------+-----------------------------------+----------------+----------------+
All the notes and other contents mentioned in the original order S.O. 938(E) dated 28.02.2024 and S.O. 1547(E),
dated 26th March, 2024 shall remain same.
[PN/255/123/2024/F F. No. 8(123)/2024/D.P./NPPA-Div.-II]
MAHAVEER SAINI, Dy. Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.
Login to read full text